NextCell Pharma AB (ST:NXTCL) — Market Cap & Net Worth
Market Cap & Net Worth: NextCell Pharma AB (NXTCL)
NextCell Pharma AB (ST:NXTCL) has a market capitalization of $13.21 Million (Skr122.76 Million) as of May 4, 2026. Listed on the ST stock exchange, this Sweden-based company holds position #26184 globally and #560 in its home market, demonstrating a -8.17% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying NextCell Pharma AB's stock price Skr1.10 by its total outstanding shares 111392959 (111.39 Million). Analyse NextCell Pharma AB cash flow conversion to see how efficiently the company converts income to cash.
NextCell Pharma AB Market Cap History: 2020 to 2026
NextCell Pharma AB's market capitalization history from 2020 to 2026. Data shows change from $212.78 Million to $13.21 Million (-36.77% CAGR).
Index Memberships
NextCell Pharma AB is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
First North Sweden PI
FNSESEKPI
|
$14.99 Billion | 0.09% | #147 of 281 |
Weight: NextCell Pharma AB's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
NextCell Pharma AB Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how NextCell Pharma AB's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.80x
NextCell Pharma AB's market cap is 0.80 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $212.78 Million | $3.56 Million | -$17.69 Million | 59.69x | N/A |
| 2021 | $93.02 Million | $3.91 Million | -$24.56 Million | 23.78x | N/A |
| 2022 | $84.39 Million | $5.59 Million | -$34.08 Million | 15.10x | N/A |
| 2023 | $31.53 Million | $10.11 Million | -$39.81 Million | 3.12x | N/A |
| 2024 | $34.04 Million | $10.66 Million | -$41.96 Million | 3.19x | N/A |
| 2025 | $8.76 Million | $10.94 Million | -$35.14 Million | 0.80x | N/A |
Competitor Companies of NXTCL by Market Capitalization
Companies near NextCell Pharma AB in the global market cap rankings as of May 4, 2026.
Key companies related to NextCell Pharma AB by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
NextCell Pharma AB Historical Marketcap From 2020 to 2026
Between 2020 and today, NextCell Pharma AB's market cap moved from $212.78 Million to $ 13.21 Million, with a yearly change of -36.77%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Skr13.21 Million | +50.75% |
| 2025 | Skr8.76 Million | -74.26% |
| 2024 | Skr34.04 Million | +7.98% |
| 2023 | Skr31.53 Million | -62.64% |
| 2022 | Skr84.39 Million | -9.28% |
| 2021 | Skr93.02 Million | -56.28% |
| 2020 | Skr212.78 Million | -- |
End of Day Market Cap According to Different Sources
On May 3rd, 2026 the market cap of NextCell Pharma AB was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $13.21 Million USD |
| MoneyControl | $13.21 Million USD |
| MarketWatch | $13.21 Million USD |
| marketcap.company | $13.21 Million USD |
| Reuters | $13.21 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About NextCell Pharma AB
NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. Its lead drug candidate is ProTrans, a cell therapy with mesenchymal stromal cells for the treatment of autoimmune and inflammatory diseases, including type-1 diabetes. The company also operates Cellaviva, a stem cell bank. The company was incorporated … Read more